MA51315A - Compositions et méthodes permettant de traiter des troubles du snc - Google Patents

Compositions et méthodes permettant de traiter des troubles du snc

Info

Publication number: MA51315A
Authority: MA; Morocco
Prior art keywords: compositions; methods; cns disorders; treating cns; treating
Prior art date: 2017-12-22

Application number

MA051315A

Other languages

English (en)

Inventor

Maria Jesus Blanco-Pillado

Boyd L Harrison

Daniel La

Albert Jean Robichaud

Francesco G Salituro

Original Assignee

Sage Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-12-22

Filing date

2018-12-21

Publication date

2020-10-28

2018-12-21 Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc

2020-10-28 Publication of MA51315A publication Critical patent/MA51315A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J21/005—Ketals
- C07J21/008—Ketals at position 17
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0007—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa
- C07J5/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/0085—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by an halogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
- C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Toxicology (AREA)
Addiction (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

MA051315A 2017-12-22 2018-12-21 Compositions et méthodes permettant de traiter des troubles du snc MA51315A (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date
US201762610069P	2017-12-22	2017-12-22
US201762611983P	2017-12-29	2017-12-29
US201862620095P	2018-01-22	2018-01-22
US201862722781P	2018-08-24	2018-08-24
US201862734718P	2018-09-21	2018-09-21

Publications (1)

Publication Number	Publication Date
MA51315A true MA51315A (fr)	2020-10-28

Family

ID=65234663

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA051315A MA51315A (fr)	2017-12-22	2018-12-21	Compositions et méthodes permettant de traiter des troubles du snc

Country Status (15)

Country	Link
US (1)	US20210101928A1 (fr)
EP (2)	EP3728284B1 (fr)
JP (3)	JP7382326B2 (fr)
KR (2)	KR20200104350A (fr)
CN (3)	CN118271387A (fr)
AU (2)	AU2018388408B2 (fr)
BR (1)	BR112020012712A8 (fr)
CA (1)	CA3086299A1 (fr)
DK (1)	DK3728284T3 (fr)
ES (1)	ES2991092T3 (fr)
IL (2)	IL275562B2 (fr)
MA (1)	MA51315A (fr)
MX (3)	MX2020006599A (fr)
TW (2)	TWI835765B (fr)
WO (1)	WO2019126741A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013112605A2 (fr)	2012-01-23	2013-08-01	Sage Therapeutics, Inc.	Formulation de stéroïde neuroactif et procédés de traitement des troubles de snc
IL275725B (en)	2012-08-21	2022-08-01	Sage Therapeutics Inc	Treatment methods for epilepsy and status epilepticus
HRP20190232T1 (hr)	2013-04-17	2019-03-22	Sage Therapeutics, Inc.	19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
WO2015195962A1 (fr)	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Stéroïdes neuroactifs, leurs compositions et utilisations
JOP20200195A1 (ar)	2014-09-08	2017-06-16	Sage Therapeutics Inc	سترويدات وتركيبات نشطة عصبياً، واستخداماتها
ES2793237T3 (es)	2014-11-27	2020-11-13	Sage Therapeutics Inc	Composiciones y métodos para el tratamiento de trastornos del SNC
CN109689673B (zh) *	2016-07-11	2023-03-14	萨奇治疗股份有限公司	C17、c20和c21取代的神经活性类固醇及其使用方法
CN115974954A (zh)	2016-08-23	2023-04-18	萨奇治疗股份有限公司	19-去甲c3,3-二取代的c21-n-吡唑基类固醇的晶体
EP3720867A1 (fr)	2017-12-08	2020-10-14	Sage Therapeutics, Inc.	Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
EP3864022B1 (fr)	2018-10-12	2023-09-20	Sage Therapeutics, Inc.	Stéroïdes neuroactifs substitués en position 10 avec un groupe cyclique pour une utilisation dans le traitement de troubles du système nerveux central
CA3124703C (fr) *	2019-01-14	2023-10-17	Beijing Xuanyi Pharmasciences Co., Ltd.	Steroides a substitution tetrazolone et utilisation de ces derniers
CN114206900A (zh)	2019-05-31	2022-03-18	萨奇治疗股份有限公司	神经活性类固醇及其组合物
WO2021023213A1 (fr) *	2019-08-07	2021-02-11	上海翰森生物医药科技有限公司	Sel et forme cristalline d'un régulateur de dérivé de stéroïde
US10857163B1 (en)	2019-09-30	2020-12-08	Athenen Therapeutics, Inc.	Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
US20230346801A1 (en)	2020-03-25	2023-11-02	Sage Therapeutics, Inc.	Use of agents for treatment of respiratory conditions
EP4172171A1 (fr)	2020-06-24	2023-05-03	Sage Therapeutics, Inc.	Stéroïdes neuroactifs 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl-substitués et compositions associées
WO2022040545A1 (fr) *	2020-08-20	2022-02-24	Intra-Cellular Therapies, Inc.	Composés organiques
IT202000021316A1 (it) *	2020-09-09	2022-03-09	Ind Chimica Srl	PROCESSO PER LA PREPARAZIONE DI (3α,5α)-3-IDROSSI-3-METIL-PREGNAN-20-ONE (GANAXOLONE)
WO2024189061A1 (fr) *	2023-03-14	2024-09-19	Curia Spain, S.A.U.	Procédé et intermédiaires pour la préparation de stéroïdes 3alpha-hydroxy-3bêta-alkyle
CN119176847A (zh) *	2023-06-21	2024-12-24	北京华睿鼎信科技有限公司	一种甾类化合物及其用途、制备方法和包含该甾类化合物的药物组合物
WO2025054447A1 (fr) *	2023-09-08	2025-03-13	The Research Foundation For The State University Of New York	Approche chimioprotéomique pour élucider le mécanisme d'action des 6-azastéroïdes avec une activité unique dans des mycobactéries

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3087940A (en) *	1959-02-03	1963-04-30	Advance Growth Capital Corp	19-methyl pregnene derivatives
GB1036418A (en) *	1962-07-09	1966-07-20	Syntex Corp	19-alkyl-steroids and process for their production
GB1380246A (en) *	1970-12-17	1975-01-08	Glaxo Lab Ltd	3alpha-hydroxy-androstanes and esters thereof
DE2438020A1 (de) *	1974-08-05	1976-02-26	Schering Ag	18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung
US5376645A (en)	1990-01-23	1994-12-27	University Of Kansas	Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3967297A (en) *	1996-08-01	1998-02-25	Cocensys, Inc.	Use of gaba and nmda receptor ligands for the treatment of migraine headache
ES2738526T3 (es)	2011-10-14	2020-01-23	Sage Therapeutics Inc	Compuestos 19-norpregnano 3,3-disustituidos, composiciones y usos de los mismos
US9512170B2 (en) *	2013-03-01	2016-12-06	Washington University	Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
HRP20190232T1 (hr) *	2013-04-17	2019-03-22	Sage Therapeutics, Inc.	19-nor c3,3-disupstituirani c21-n-pirazolil steroidi i postupci za njihovu upotrebu
SMT202100048T1 (it)	2013-08-23	2021-03-15	Sage Therapeutics Inc	Steroidi neuroattivi, composizioni e loro usi
HUE050028T2 (hu) *	2014-05-29	2021-12-28	Sage Therapeutics Inc	Neuroaktív szteroidok, készítmények és alkalmazásuk
WO2015195962A1 (fr) *	2014-06-18	2015-12-23	Sage Therapeutics, Inc.	Stéroïdes neuroactifs, leurs compositions et utilisations
JP6742308B2 (ja)	2014-10-16	2020-08-19	セージセラピューティクス，インコーポレイテッド	Ｃｎｓ障害を処置するための組成物および方法
AU2015331749A1 (en) *	2014-10-16	2017-05-04	Sage Therapeutics, Inc.	Compositions and methods for treating CNS disorders
ES2793237T3 (es) *	2014-11-27	2020-11-13	Sage Therapeutics Inc	Composiciones y métodos para el tratamiento de trastornos del SNC
US10329320B2 (en) *	2015-02-20	2019-06-25	Sage Therapeutics, Inc.	Neuroactive steroids, compositions, and uses thereof
WO2016164763A1 (fr)	2015-04-10	2016-10-13	Sage Therapeutics, Inc.	Compositions et méthodes permettant de traiter des troubles du snc
BR112021010996A2 (pt) *	2018-12-05	2021-08-31	Sage Therapeutics, Inc.	Esteroides neuroativos e seus métodos de uso

2018
- 2018-12-21 MA MA051315A patent/MA51315A/fr unknown
- 2018-12-21 DK DK18839991.9T patent/DK3728284T3/da active
- 2018-12-21 CN CN202311667604.7A patent/CN118271387A/zh active Pending
- 2018-12-21 KR KR1020207021156A patent/KR20200104350A/ko active Pending
- 2018-12-21 IL IL275562A patent/IL275562B2/en unknown
- 2018-12-21 CN CN202311667677.6A patent/CN117946202A/zh active Pending
- 2018-12-21 CN CN201880089688.1A patent/CN111770929B/zh active Active
- 2018-12-21 EP EP18839991.9A patent/EP3728284B1/fr active Active
- 2018-12-21 MX MX2020006599A patent/MX2020006599A/es unknown
- 2018-12-21 US US16/955,714 patent/US20210101928A1/en active Pending
- 2018-12-21 AU AU2018388408A patent/AU2018388408B2/en active Active
- 2018-12-21 BR BR112020012712A patent/BR112020012712A8/pt unknown
- 2018-12-21 KR KR1020257031726A patent/KR20250142939A/ko active Pending
- 2018-12-21 WO PCT/US2018/067277 patent/WO2019126741A1/fr not_active Ceased
- 2018-12-21 JP JP2020534229A patent/JP7382326B2/ja active Active
- 2018-12-21 ES ES18839991T patent/ES2991092T3/es active Active
- 2018-12-21 EP EP24195188.8A patent/EP4442695A3/fr active Pending
- 2018-12-21 CA CA3086299A patent/CA3086299A1/fr active Pending
- 2018-12-21 IL IL310454A patent/IL310454A/en unknown
- 2018-12-22 TW TW107146678A patent/TWI835765B/zh active
- 2018-12-22 TW TW113106858A patent/TWI892480B/zh active
2020
- 2020-07-13 MX MX2023005098A patent/MX2023005098A/es unknown
- 2020-07-13 MX MX2023005099A patent/MX2023005099A/es unknown
2023
- 2023-06-07 JP JP2023093975A patent/JP7670754B2/ja active Active
2024
- 2024-03-05 AU AU2024201459A patent/AU2024201459A1/en active Pending
2025
- 2025-02-05 JP JP2025017660A patent/JP2025072521A/ja active Pending

Also Published As

Publication number	Publication date
KR20200104350A (ko)	2020-09-03
CN111770929B (zh)	2023-12-26
MX2020006599A (es)	2020-11-06
JP7382326B2 (ja)	2023-11-16
US20210101928A1 (en)	2021-04-08
EP4442695A2 (fr)	2024-10-09
JP2025072521A (ja)	2025-05-09
IL275562B2 (en)	2024-07-01
TWI835765B (zh)	2024-03-21
MX2023005099A (es)	2023-05-23
BR112020012712A2 (pt)	2020-11-24
EP3728284A1 (fr)	2020-10-28
IL275562B1 (en)	2024-03-01
BR112020012712A8 (pt)	2022-03-03
DK3728284T3 (da)	2024-10-28
CA3086299A1 (fr)	2019-06-27
EP3728284B1 (fr)	2024-08-21
CN118271387A (zh)	2024-07-02
WO2019126741A1 (fr)	2019-06-27
AU2024201459A1 (en)	2024-03-21
AU2018388408B2 (en)	2023-12-21
ES2991092T3 (es)	2024-12-02
JP2021506890A (ja)	2021-02-22
JP2023113862A (ja)	2023-08-16
CN111770929A (zh)	2020-10-13
TW201929864A (zh)	2019-08-01
IL275562A (en)	2020-08-31
JP7670754B2 (ja)	2025-04-30
CN117946202A (zh)	2024-04-30
RU2020123943A (ru)	2022-01-24
EP4442695A3 (fr)	2025-01-22
TW202448480A (zh)	2024-12-16
MX2023005098A (es)	2023-05-24
IL310454A (en)	2024-03-01
AU2018388408A1 (en)	2020-07-09
TWI892480B (zh)	2025-08-01
KR20250142939A (ko)	2025-09-30

Publication	Publication Date	Title
MA51315A (fr)	2020-10-28	Compositions et méthodes permettant de traiter des troubles du snc
MA51316A (fr)	2020-10-28	Compositions et méthodes permettant de traiter les troubles du snc
IL291533A (en)	2022-05-01	Compounds and preparations including them for the treatment of diseases of the central nervous system
EP3452028A4 (fr)	2020-04-15	Compositions et méthode pour traiter des troubles acide-base
EP3364993A4 (fr)	2019-08-28	Procédés pour traiter le syndrome d'angelman et des troubles associés
SMT202100113T1 (it)	2021-05-07	Composizioni e metodi per trattare disturbi del snc
LT3206493T (lt)	2020-08-25	Kompozicijos ir būdai, skirti cns sutrikimams gydyti
EP3349760A4 (fr)	2019-03-27	Compositions et méthodes destinées à traiter les troubles neurologiques
SI3224269T1 (sl)	2020-10-30	Sestavki in metode za zdravljenje CNS motenj
EP3359668A4 (fr)	2019-06-05	Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
EP3703706A4 (fr)	2022-04-27	Compositions et méthode pour traiter des troubles acide-base
MA51074A (fr)	2020-10-14	Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP3445368A4 (fr)	2019-12-18	Composés et procédés pour traiter des états neurologiques et cardiovasculaires
EP3328898A4 (fr)	2019-01-23	Compositions d'agoniste trkb ou trkc et méthodes de traitement de troubles otiques
EP3280420A4 (fr)	2018-11-21	Compositions et méthodes permettant de traiter des troubles du snc
EP3324960A4 (fr)	2019-01-23	Procédés permettant de traiter des troubles associés à l'angiogenèse et à une néovascularisation
EP3297702A4 (fr)	2019-01-16	Méthodes et compositions permettant de traiter des troubles associés au vieillissement
EP3471746A4 (fr)	2020-02-26	Méthode et composition pour traiter des troubles epileptiques
EP3454885A4 (fr)	2019-12-25	Peptides et méthodes permettant de traiter des troubles neurodégénératifs
EP3334710A4 (fr)	2019-04-03	Compositions et méthodes de traitement et de prévention de troubles neurodégénératifs
EP3661492A4 (fr)	2021-04-14	Procédés et compositions pour traiter des troubles neurologiques
EP3445369A4 (fr)	2020-03-04	Compositions et méthodes pour traiter la démence
EP3697354A4 (fr)	2021-06-30	Compositions et méthodes pour traiter des troubles oculaires
EP3519050A4 (fr)	2020-06-17	Compositions et méthodes de traitement de troubles ophtalmologiques
EP3610019A4 (fr)	2021-05-12	Compositions et méthodes pour traiter des troubles douloureux